Droxidopa Floating Sustained Release Tablet Formulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current Droxidopa formulations are unstable in alkaline pH conditions and require frequent dosing, leading to suboptimal bioavailability and patient compliance issues.
Innovation Solution
Development of sustained release floating tablets using a combination of Droxidopa, controlled release polymers, effervescent agents, and gas generating agents like sodium bicarbonate, which maintain buoyancy in gastric acid for over 12 hours, reducing dosing frequency and enhancing bioavailability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If immediate release oral capsules are used, then the drug can be quickly absorbed, but the dosing frequency must be high (three times daily) and bioavailability is suboptimal
Solution Approach 1:
The patent applies dynamics by transitioning from static immediate release to dynamic sustained release, where the tablet progressively releases the drug over time. The floating tablet maintains gastric retention dynamically for 8-12 hours, adapting the drug delivery to match the physiological needs and improving bioavailability while reducing dosing frequency from three times to twice daily or less.
Solution Approach 2:
The patent changes key parameters by modifying the physical state and release characteristics of the tablet. By incorporating effervescent agents (sodium bicarbonate, citric acid) and floating materials, the tablet changes from sinking to floating state, extending gastric retention time from minutes to hours. This parameter change enables sustained release and improves overall drug bioavailability.
2Duration of action of moving object
If the tablet floats on gastric fluid, then the drug release is sustained for extended period, but the formulation complexity increases
Solution Approach 1:
The patent merges multiple functions into a single floating tablet formulation. The effervescent agents (sodium bicarbonate and citric acid) serve dual purposes: generating gas for floating and potentially enhancing drug dissolution. The controlled release polymer matrix simultaneously provides structural integrity, sustained release mechanism, and floating capability when combined with the gas-generating agents. This merging reduces the need for separate complex multi-layer structures.
Solution Approach 2:
The patent uses composite materials by combining Droxidopa with effervescent agents (sodium bicarbonate, citric acid), floating materials, and controlled release polymers in a single matrix. This composite formulation achieves floating behavior and sustained release simultaneously without requiring multiple separate components or complex assembly, thereby managing formulation complexity while extending drug release duration to 8-12 hours.
3Ease of operation
If dosing frequency is reduced, then patient compliance improves, but maintaining stable drug levels becomes more challenging
Solution Approach 1:
The patent achieves continuity of useful action through sustained release mechanism that maintains steady drug release over 8-12 hours. The floating tablet remains in the stomach for an extended period, providing continuous drug release rather than rapid release followed by clearance. This continuous action maintains stable drug levels in the bloodstream, enabling reduced dosing frequency while improving patient compliance and maintaining therapeutic efficacy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The sustained release floating tablets provide a prolonged release of Droxidopa for 10-12 hours, improving patient compliance and bioavailability by maintaining stability in acidic pH and reducing dosing frequency to twice daily.
Implementation Method 1
effervescent agents, and gas generating agents like sodium bicarbonate
Implementation Method 2
maintain buoyancy in gastric acid for over 12 hours
Implementation Method 3
sustained release Droxidopa tablets... releases Droxidopa in sustained manner for a period of 10-12 hours
Implementation Method 4
controlled release polymer
Data Source
AI summary
The present invention to unit dosage forms which are capable of floating on gastric fluid and delivering the therapeutic agent over an extended period of time. Particularly the invention relates to Droxidopa sustained release gastroretentive dosage form for release of drug over period of 12 hrs. The gastroretentive dosage form of Droxidopa of the present invention comprises drug, polymer (Hydroxy propyl methyl cellulose K200M) as rate controlling polymer and the formulation maintains buoyancy on the gastric fluid for a period of 12 hrs, thus providing better patient compliance by providing reducing dosing frequency.